Trump Administration Reverses Biden's Plan For Medicare Coverage Of Obesity Drugs Like Ozempic And Zepbound
Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.
LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now?
Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Lilly markets its dual GIP and GLP-1 receptor agonist, ...
Beyond weight loss: Can Ozempic sharpen your brain, cut dementia risk?
Weight loss drugs like Ozempic gained popularity for managing obesity, diabetes, and related chronic conditions, a new study ...
The Print6h
Big buzz over Mounjaro launch but here’s why India’s anti-obesity drug market may only take off next yr
India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...
Push for obesity drug coverage hits major roadblock
Subscribe to TheStreet's free daily newsletter 💰💵 Dr. Wilson's statement might sound hyperbolic, but the United States has seen nearly continuous rises in obesity rates for decades. However, for the ...